Trial Profile
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs CB 708 (Primary) ; Pembrolizumab (Primary)
- Indications Haematological malignancies; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms STAMINA; STAMINA-001
- Sponsors Antengene Corporation
- 22 Mar 2024 According to an Antengene Corporation media release, to date 23 patients have been enrolled and received a first tumor assessment. Completion of Phase I dose escalation and proceed to dose expansion in H1 2024.
- 28 Aug 2023 According to an Antengene Corporation media release, a total of 13 patients have started the combination treatment.
- 23 Feb 2023 Planned number of patients changed from 36 to 98.